CROs/Service Providers

ProTrials creates U.K. subsidiary

Tuesday, January 24, 2012 10:40 AM

Sunnyvale, Calif.-based CRO ProTrials Research has created a wholly owned subsidiary to help meet its sponsors’ increasing needs for multi-national, multi-site clinical trials.  Based in the United Kingdom, ProTrials Global will help manage ongoing clinical trials in Italy, Spain and the U.K., and will be responsible for additional growth in the European arena.

More... »


inVentiv Health to acquire SDI businesses from IMS Health

Friday, January 20, 2012 02:53 PM

Burlington, Mass.-based inVentiv Health will acquire certain promotional and medical audit businesses of SDI Health, which IMS Health has committed to divest in connection with obtaining regulatory approval of its acquisition of SDI.  Financial terms were not disclosed.

More... »


CoreLab Partners opens office in Tokyo

Friday, January 20, 2012 02:50 PM

Signaling its plan to expand its business model in the Pacific Rim and build a global presence as a large imaging and cardiac safety core lab, CoreLab Partners is opening of an office in Tokyo under the wholly owned subsidiary CoreLab Partners Japan.

More... »

Quintiles launches innovative Center of Excellence in China

Wednesday, January 18, 2012 04:09 PM

Quintiles is opening a business process outsourcing (BPO) and project management center of excellence in Dalian, China, a major city with a multilingual workforce and location ideally suited to serve the Japanese, Chinese and South Korean biopharmaceutical markets.

More... »

Nikem Research and Dualsystems Biotech form alliance

Monday, January 9, 2012 01:48 PM

Nikem Research and Dualsystems Biotech have joined forces to jointly offer their respective drug/target profiling and drug discovery services to their clients.

More... »

ICON named sole provider of central lab services to Shire

Monday, January 9, 2012 01:45 PM

CRO ICON has signed a strategic partnership with Shire Specialty Pharmaceuticals to serve as the sole global provider of central laboratory services and one of two strategic partners for clinical development services.

More... »

AMRI announces additional actions to streamline operations

Monday, January 9, 2012 01:40 PM

Albany Molecular Research (AMRI) took steps in the fourth quarter of 2011 to align the business to current and expected market conditions, including reducing the company’s workforce, right size capacity and reduce operating costs for 2012.

More... »

Alexion to acquire Enobia Pharma for $610 million

Tuesday, January 3, 2012 01:39 PM

Alexion Pharmaceuticals and Enobia Pharma have signed a definitive agreement under which Alexion will acquire 100% of the capital stock of Enobia. Enobia is a private biopharmaceutical company based in Montreal, Canada and Cambridge, Massachusetts, which is focused on the development of therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders.

More... »

Quintiles forms Digital Patient Unit

Tuesday, January 3, 2012 01:14 PM

Quintiles has formed a Digital Patient unit which brings together the company’s online communities and digital expertise to directly engage patients.

More... »

Baxter, Momenta enter $33 million biosimilar development agreement

Friday, December 23, 2011 12:29 PM

Baxter International and Momenta Pharmaceuticals have entered into a global collaboration to develop and commercialize follow-on biologic products, also known as biosimilars. Biosimilars replicate existing, branded biologics used in the treatment of a variety of diseases including cancer, autoimmune disorders and other chronic conditions. With this collaboration, Baxter will leverage its leading clinical development and biologic manufacturing expertise, global leadership in sterile injectables and global commercial capabilities, while Momenta will provide its expertise in high-resolution analytics, characterization, and product and process development.

More... »

`

CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs